Preventing Lymphomas in Transplanted Children

A new antigen/adjuvant combination preventing the proliferation of infected lymphocytes in transplanted children (in-licensed product).

This orphan drug (status granded in Europe, pending in the US) has to go through phase II and III clinical trials. Henogen thus expects to produce and distribute the product on its own.